Tercica announced that they just started a Phase II clinical trial examining the efficacy of IGF-1 stacked with human growth hormone (GH). Unfortunately for bodybuilders and athletes, the outcome measure in this study is not performance enhancement, increases in lean muscle mass, or loss in body fat.
The objective is to measure “height velocity” and safety in the treatment of short stature in children. The trial will examing the efficacy of three different stacks of GH + IFG-1 and compare them with GH alone (GH monotherapy).
Potential of GH/IGF-1 Combination Product: The combination product will be studied in children with short stature not associated with growth hormone deficiency, who also have low IGF-1 levels. A potential cause of short stature in this group of patients could be a suboptimal IGF-1 secretion in response to growth hormone stimulation alone. Pre-clinical studies suggest that co-administration of GH and IGF-1 may increase specific growth responses greater than growth hormone alone. Therefore, Tercica believes that treatment with a combination of both GH and IGF-1 may be superior to monotherapy of growth hormone alone in a subpopulation of children with low IGF-1 and short stature not associated with growth hormone deficiency.
Tercica is the biotechnology company that is the first to bring FDA-approved recombinant insulin-like growth factor-1 (IGF-1) to the marketplace. The brand name for IGF-1 is Increlex and the generic name is mecasermin.
Tercica reached an agreement in July 2007 with Genentech to use Genentech recombinant human growth hormone Nutropin AQ (somatropin) in a stack with IGF-1. Genentech bought 708,591 shares of Tercica stock for about $4 million as part of agreement.
It is interesting that discussion of the use of growth hormone and IGF-1 in athletes for performance enhancing purposes revolves around the extremely dangerous side effects of these drugs; efforts to prevent GH use in sports is often based on the dangers of the drugs and potential public health crisis they may cause.
Yet a news story about the therapeutic use of growth hormone and IGF-1 in children gets buried in the news.
About the author
Millard writes about anabolic steroids and performance enhancing drugs and their use and impact in sport and society. He discusses the medical and non-medical uses of anabolic-androgenic steroids while advocating a harm reduction approach to steroid education.
No replies yet
Loading new replies...
Join the full discussion at the MESO-Rx →